other material
confidence high
sentiment positive
materiality 0.55
Jade Biosciences reports preclinical JADE301 data in dermatomyositis; Phase 1 in 24 healthy volunteers to start Q4 2026
Jade Biosciences, Inc.
- JADE301 binds IFN-β with KD of 11.3 pM, ~2.5-fold higher affinity than the dazukibart comparator, with no detectable binding to other interferon family proteins.
- Inhibited pSTAT induction with IC50 of 13 pM (~2.5-fold more potent than dazukibart) and MX-1 in human dermal fibroblasts with IC50 of 11 pM (~8-fold more potent).
- NHP data: ~30-day half-life after 30 mg/kg IV (~3x longer than dazukibart) and ~25-day SC half-life; modeled human SC bioavailability ~73%-75% vs dazukibart's ~43%-44%.
- GLP NHP toxicology: SC JADE301 every two weeks at 0, 50, 100 and 200 mg/kg was well tolerated; no treatment-related adverse clinical, lab or histopathology findings.
- Phase 1 placebo-controlled single ascending-dose SC trial in 24 healthy volunteers to start Q4 2026; interim data anticipated in the second half of 2027.